No Data
No Data
No Data
No Data
No Data
康灃生物-B:2023年年報
Futu NewsApr 25 18:36 · Announcements
Kang Feng Bio-B (06922.HK): The Stock Exchange granted listing approval to implement full circulation of H shares
Gelonghui, April 3 | Kang Feng Bio-B (06922.HK) announced that the company has applied to the Stock Exchange Listing Committee to approve 29,341,981 H shares of the company, that is, the maximum number of unlisted shares of the company to be converted, listed and traded under the conversion and listing. The Company is pleased to announce that on April 3, 2024, the Stock Exchange has granted listing approval, which is subject to all other conditions for conversion and listing before it can be implemented.
Gelonghui FinanceApr 3 19:33
Kang Feng Bio-B (06922) announced 2023 results. Loss attributable to parent company owners of 97.486 million yuan narrowed 13.13% year-on-year
Kang Feng Bio-B (06922) announced its 2023 results, with revenue of about 40.95 million yuan, an increase of 50.8 over the previous year...
Zhitong FinanceMar 27 22:07
CRYOFOCUS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 27 21:49 · Announcements
Kang Feng Bio-B (06922.HK) plans to hold a board meeting on March 27 to approve the annual results
Gelonghui, March 13 | Kang Feng Bio-B (06922.HK) issued an announcement. The board of directors is pleased to hold a board meeting on March 27, 2024 (Wednesday) to review and approve the Group's annual results and announcements for the year ended 31 December 2023, as well as to consider the payment of a final dividend (if any).
Gelonghui FinanceMar 13 16:54
康灃生物-B:董事會會議日期
Futu NewsMar 13 16:51 · Announcements
No Data
No Data